YAMAMOTO RESEARCH
|
|||||||||||||||
 YAMAMOTO® RESEARCH
Yamamoto® Research Saccharomyces Boulardii Lynside® Pro SCB Intestinal flora*
Saccharomyces Boulardii Lynside® Pro SCB is a food supplement of probiotics, which promote the balance of intestinal flora*. The product provides 6 billions of colony-forming units of Saccharomyces cerevisiae var. boulardii per daily dose. Saccharomyces boulardii is a non-pathogenic probiotic yeast, which exerts a direct constricting effect on many pathogens that has been used in Europe for decades in treating different types of diarrhoea. It is commonly used in the medical field to prevent diarrhoea associated with antibiotic therapy or nasogastric feeding, as well as for the treatment of acute diarrhoea in adults and children or those associated with Clostridium difficile and even chronic diarrhoea in patients with HIV infection. Among the "non-bacterial" probiotics, the only real efficacy confirmed for some time is Saccharomyces boulardii ("Sb"), being the only "therapeutic" yeast species whose benefit as a probiotic has been demonstrated in literature (see the "Marchand and Vandenplas" study, 2000). To date, over 40 clinical studies and more than 40 pharmacological studies have been published on this precious Saccharomyces boulardii (McFarland, 2010), and thanks to this availability of clinical evidence, this therapeutic yeast is recommended by the European Society of Paediatric Gastroenterology, Hepatology and Nutrition (ESPGHAN) for the treatment of all types of acute diarrhoea in children (Guarino et al, 2014).
The Saccharomyces boulardii is a wild tropical yeast discovered in Indochina in 1923 by the French scientist Henri Boulard, who managed to isolate it from the peel of various tropical fruits (lychee and mangosteen) after finding that the indigenous peoples used the peel of these tropical fruits as anti-diarrhoea drugs. This peculiarity is favoured because in humans, Saccharomyces boulardii does not colonise the intestinal system permanently and already after 6-7 days from the interruption of the administration, the relative cells are no longer detectable in the faeces. Because of its "not being a bacterium", its pharmacokinetic properties of absorption, metabolism, distribution and elimination are very different from the other so-called "bacterial" probiotics, because it passes through the intestine and is neither absorbed nor metabolised. Once administered orally, it resists the gastric environment and biliary acids, reaching the intestine alive and effective, without being absorbed reaching "steady-state" concentrations within 3 days, and it is eliminated within 5 days after the treatment stops. A very important feature, which is why it has been used for so long in clinical settings, is its resistance to antibiotics. Saccharomyces B. is not deactivated by antibiotic drugs and therefore can be taken at the same time, while bacteria are almost always killed (Graff et al, 2008). This is in fact why it is so commonly used just in conjunction with antibiotic therapies to prevent the diarrhoea that they cause. Another interesting feature that differentiates this yeast from its other bacterial "probiotic colleagues" is its surface area, which is about 10 times greater than that of bacteria. This involves some specific activities, such as competition of the substrates, and a sort of "magnet effect" against pathogens (Billoo et al, 2006, McFarland 2010). The clinical efficacy of Saccharomyces boulardii has been evaluated in several types of acute diseases, starting from antibiotic diarrhoea, Clostridium difficile infections, Helicobacter pylori infection, acute diarrhoea in adults and children (where it finds extensive application), diarrhoea related to enteral nutrition, the annoying diarrhoea experienced by travellers, Vibrio cholerae infection, amoebic dysentery, and various other infections. In addition, the clinical efficacy of Saccharomyces boulardii has been evaluated in several types of chronic inflammatory diseases, including very serious ones such as Crohn's disease, the most "common" irritable bowel syndrome, ulcerative colitis, giardiasis, amoebic colitis, and even in diarrhoea associated with HIV. It is however a fact that both in children and adults, diarrhoea is often a problem with fairly sudden onset and with a duration ranging from a few days to several weeks. Its severity then depends on its aetiology which may be a food contamination, an intoxication, a bacterial infection, or more commonly a viral (such as "seasonal" gastroenteritis) or parasitic infection. Also in these cases some of the different studies available were conducted to evaluate the effect of Saccharomyces boulardii in the treatment of acute diarrhoea, where the efficacy of Saccharomyces boulardii is confirmed in particular in cases of acute gastroenteritis in children, where the results suggest that the treatment strengthens the immune response significantly. Studies have also shown that Saccharomyces boulardii, as an adjuvant treatment of re-hydration solutes, reduces the duration of diarrhoea, speeding recovery and reducing the risk of prolonged diarrhoea. Many studies indicate that the Saccharomyces Boulardii yeast interacts with many molecular mechanisms associated with intestinal inflammation, encouraging the reduction of inflammation typical of colitis, including histological damage, in addition to diarrhoea and in the intestinal mucous. It decreases levels of various IL-1ß, IL-6, TNF-α and iNOS pro-inflammatory mediators, promoting the secretion of IL-10 anti-inflammatory cytokine. In addition, Saccharomyces Boulardii also reduces the colonisation of the intestine by Candida albicans. The efficacy of Saccharomyces boulardii increases when it is administered within the first 48 hours after the onset of the disease, with a duration of use ranging from 7 days to 6 months taken as a single treatment or as additional adjuvant therapy of course depending on the pathology (McFarland 2010). Directions: take 1 capsule a day before meal, preferably on an empty stomach.
|
| 30 capsules |
|
| Mean analysis | |
| Serving size (1 capsule) | |
| Per serving size (1 capsule) | |
| Saccharomyces cerevisiae var. boulardii CNCM: I-3799 of which live cells |
300 mg 6 bil cfu |
|
Ingredients: Lynside® Pro SCB (Saccharomyces cerevisiae var. boulardii CNCM: I-3799, 20 bil cfu/g), capsule (glazing agent: hydroxypropyl methylcellulose; colour: titanium dioxide), bulking agent: microcrystalline cellulose; anti-caking agents: magnesium salts of fatty acids, silicon dioxide.
|
|
Copyright © 2007-2023 IAF NETWORK S.p.A. - All Rights Reserved C.f. e P.Iva 02424060982 - REA: BS-448778 - email: help@iafnetwork.com
WA
